Skip to content
Relatix Bio

Relatix Bio

Radically different

  • Services
  • Knowledgebase
  • Partnerships
  • Our Approach
  • Contact
  • About
    • Vision
    • Our mission
    • Privacy Policy
    • FAQ
    • News
Posted on July 27, 2026 by admin
<![CDATA[Phase 2 ZEPHYR finds oral betovumeline combo reduces PANSS and improves cognition in acute schizophrenia, with generally mild side effects.]]>
CategoriesImported News TagsClinical trial, News Approved, Schizophrenia spectrum

Post navigation

Previous PostPrevious OpenAI called the Hugging Face attack unprecedented. But we’ve been here before. 
Next PostNext STAT+: Pharma’s drug spending deflection

This is the footer

Privacy Policy Proudly powered by WordPress